Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (symbol: KURA) is a clinical-stage biopharmaceutical company based in San Diego, dedicated to pioneering precision medicines for cancer treatment. Leveraging advances in cancer genomics, Kura develops targeted therapies and companion diagnostics designed to address the genetic underpinnings of various cancers, optimizing treatment efficacy and safety.
The company's flagship product candidate, Tipifarnib, is under investigation for treating both solid tumors and blood cancers. Tipifarnib is a potent farnesyl transferase inhibitor, currently undergoing Phase 1/2 trials in combination with alpelisib for patients with head and neck squamous cell carcinoma.
Another key candidate, Ziftomenib, targets acute myeloid leukemia (AML) with NPM1 and KMT2A mutations. Highlighted by its recent Breakthrough Therapy Designation from the FDA, Ziftomenib is involved in multiple clinical trials, including the KOMET-001 and KOMET-007 studies. Early results show promising efficacy and a favorable safety profile, particularly in the combination with current standards of care like venetoclax and azacitidine.
Kura is also advancing KO-2806, a next-generation farnesyl transferase inhibitor, in a Phase 1 dose-escalation trial as a monotherapy and in combination with other targeted therapies for renal and lung cancers.
Financially, Kura remains robust, with cash reserves projected to support operations through 2027. The company has an ongoing commitment to aggressive research, development, and pre-commercial activities, ensuring continued progression of its promising pipeline.
The company's recent achievements include reporting preliminary clinical data from the KOMET-007 trial and securing additional financing to reinforce its financial position. Kura continues its mission to bring life-saving therapies to patients with high unmet medical needs, aiming to improve and extend the lives of those battling cancer.
Kura Oncology, a clinical-stage biopharmaceutical company, announced that its CEO, Troy Wilson, will participate in two investor conferences. The first is a fireside chat at the Evercore ISI HealthCONx Conference on November 29, 2022, at 12:35 p.m. ET. The second is at the JMP Securities Hematology and Oncology Summit on December 7, 2022, at 12:20 p.m. ET. Audio webcasts will be available on Kura's website with archived replays after each event. Kura focuses on precision cancer medicines, with candidates like Ziftomenib in clinical trials.
Kura Oncology (Nasdaq: KURA) has announced that four abstracts concerning ziftomenib, a selective menin inhibitor, have been accepted for presentation at the ASH Annual Meeting on December 10-13, 2022, in New Orleans. Notable is the oral presentation of updated data from the KOMET-001 trial on ziftomenib for treating relapsed/refractory acute myeloid leukemia (AML). These presentations aim to showcase ziftomenib's potential impact on patient outcomes within this critical unmet need.
Kura Oncology reported third quarter 2022 results, highlighting the acceptance of updated KOMET-001 trial data for oral presentation at ASH. The company secured a $25 million equity investment from Bristol Myers Squibb and a $125 million term loan from Hercules Capital, extending financial runway into 2026. Key developments include positive preliminary results for tipifarnib plus alpelisib in HNSCC and the closure of AIM-HN trial to further enrollment. The net loss for Q3 2022 was $35.5 million, with R&D expenses rising to $25 million.
Kura Oncology (Nasdaq: KURA) announced a $25 million equity investment from Bristol Myers Squibb at $18.25 per share and a term loan facility of up to $125 million from Hercules Capital. The funds will support Kura's operations into 2026 if fully drawn. The loan includes an immediate draw of $10 million and potential additional tranches tied to clinical milestones. This collaboration aims to advance Kura's cancer treatments, enhancing their financial strength and strategic development capabilities.
Kura Oncology, Inc. (Nasdaq: KURA) announced that CEO Troy Wilson will participate in two investor conferences. The first is a fireside chat at the Credit Suisse Healthcare Conference on November 9, 2022, at 1:25 p.m. ET in Ranch Palos Verdes, CA. The second will be at the Jefferies Global Healthcare Conference in London on November 16, 2022, at 3:15 p.m. GMT. Audio webcasts of both events will be available on Kura's website, along with archived replays.
Kura Oncology focuses on precision medicines for cancer treatment, with several clinical trials ongoing, including for ziftomenib and tipifarnib.
Kura Oncology, Inc. (Nasdaq: KURA) will report its third quarter 2022 financial results before U.S. markets open on November 3, 2022. Management will host a conference call at 8:00 a.m. ET to discuss the results and provide a corporate update. Kura is focused on precision medicines for cancer treatment, with a pipeline including Ziftomenib, currently in trials for acute myeloid leukemia, and Tipifarnib, which has Breakthrough Therapy Designation for HRAS mutant head and neck cancer. A live webcast will also be available for investors.
Kura Oncology has reported promising preliminary results from its Phase 1/2 KURRENT-HN trial, demonstrating the potential of the combination therapy of tipifarnib and alpelisib in treating HRAS and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC). A notable case showed a patient achieving an 81% reduction in target lesions after one cycle of the combination therapy. The trial aims to assess the safety and efficacy of this combination, targeting about 45% of HNSCC tumors with actionable mutations.
Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer treatments, announced that CEO Troy Wilson will participate in the H.C. Wainwright 24th Annual Global Investment Conference. A pre-recorded presentation will be accessible on-demand starting September 12, 2022, at 7:00 a.m. ET. The presentation will be available for 90 days in the Investors section of Kura's website. The company is advancing several drug candidates, including Ziftomenib for acute myeloid leukemia and Tipifarnib for HRAS mutant head and neck cancer.
Kura Oncology reported its Q2 2022 financial results and highlighted significant advancements in its clinical programs. The company identified a recommended Phase 2 dose for ziftomenib, pending FDA review, and enrolled an additional 18 patients in the KOMET-001 trial targeting acute myeloid leukemia. They observed preliminary efficacy in the KURRENT-HN trial of tipifarnib with alpelisib. Kura holds $450 million in cash and equivalents, expected to fund operations through 2024.
Kura Oncology, a clinical-stage biopharmaceutical company focused on cancer treatments, will participate in the Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022. CEO Troy Wilson will be on a panel titled “Bullseye - Targeted Oncology – In with the New,” scheduled for 10:20 AM ET. A live audio webcast will be available on Kura's website, with a replay to follow. The company is advancing its pipeline, including Ziftomenib in a Phase 1b trial for relapsed AML, while Tipifarnib is in registration trials for HRAS mutant HNSCC.
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
What is Kura Oncology's core business?
What are the main product candidates of Kura Oncology?
What is Tipifarnib used for?
What recent achievements has Kura Oncology reported?
What is Ziftomenib?
How is Ziftomenib being tested currently?
What financial position is Kura Oncology in?
What is KO-2806?
Where is Kura Oncology based?
How can investors get in touch with Kura Oncology?
